Fayaz Master

Fayaz joined Scancell from Allergy Therapeutics where he was the Head of Clinical Development, responsible for the clinical development of a mosaic virus-like particle. Prior to this, he held senior oncology Clinical Development/Operation roles at ClinMed and BTG, a UK-based specialty pharmaceutical company. Fayaz led the clinical operations team responsible for generating clinical evidence for TheraSphere, a radioembolization therapy in patients with primary and metastatic colorectal cancer. Fayaz has just under 20 years of clinical operations experience in early and late-stage global oncology clinical development.